Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fresh Tracks Therapeutics Inc V.BBI


Primary Symbol: FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.


GREY:FRTX - Post by User

Fresh Tracks Therapeutics Inc > Dividend policy
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(185)
•••
Comment by Seppelton Oct 10, 2022 9:32am
180 Views
Post# 35015548

RE:RE:RE:RE:RE:RE:RE:Dividend policy

RE:RE:RE:RE:RE:RE:RE:Dividend policyRiverstone and GMT Capital have already reported the conversion of preferred to common. The company will probably issue a press release and new presentation. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities